Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Interest Expenses (2016 - 2019)

Fate Therapeutics (FATE) has disclosed Interest Expenses for 7 consecutive years, with $543000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Interest Expenses rose 26.28% year-over-year to $543000.0, compared with a TTM value of $543000.0 through Sep 2020, down 66.87%, and an annual FY2019 reading of $1.8 million, up 3.3% over the prior year.
  • Interest Expenses was $543000.0 for Q4 2019 at Fate Therapeutics, up from $400000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $600000.0 in Q1 2015 and bottomed at -$56000.0 in Q4 2017.
  • Average Interest Expenses over 5 years is $393611.1, with a median of $410500.0 recorded in 2018.
  • The sharpest move saw Interest Expenses surged 2042.86% in 2015, then crashed 117.02% in 2017.
  • Year by year, Interest Expenses stood at $600000.0 in 2015, then crashed by 45.17% to $329000.0 in 2016, then crashed by 117.02% to -$56000.0 in 2017, then skyrocketed by 867.86% to $430000.0 in 2018, then rose by 26.28% to $543000.0 in 2019.
  • Business Quant data shows Interest Expenses for FATE at $543000.0 in Q4 2019, $400000.0 in Q3 2019, and $409000.0 in Q2 2019.